AJAC  Vol.1 No.2 , August 2010
Quantitative Application to a Polypill by the Development of Stability Indicating LC Method for the Simultaneous Estimation of Aspirin, Atorvastatin, Atenolol and Losartan Potassium
Abstract: Polypill is a fixed-dose combination (FDC) containing three or more drugs in a single pill with the intention of reducing the number of tablets or capsules that need to be taken. Developing a single analytical method for the estimation of individual drugs in a Polypill is very challenging, due to the formation of drug-drug and drug-excipients interaction impurities. Here an attempt was made to develop a new, sensitive, single stability-indicating HPLC method for the simultaneous quantitative determination of Aspirin (ASP) Atorvastatin (ATV), Atenolol (ATL) and Losartan potassium (LST) in a polypill form in the presence of degradation products. Efficient chromatographic separation was achieved on a C18 stationary phase with simple mobile phase combination of buffer and Acetonitrile. Buffer consists of 0.1% Orthophosphoric acid (pH 2.9), delivered in a gradient mode and quantitation was carried out using ultraviolet detection at 230 nm with a flow rate of 1.0 mL/min. The retention times of Atenolol, Aspirin, Losartan potassium, and Atorvastatin were 3.3, 7.6, 10.7 and 12.9 min respectively. The combination drug product are exposed to thermal, acid/base hydrolytic, humidity and oxidative stress conditions, and the stressed samples were analyzed by proposed method. The method was validated with respect to linearity; the method was linear in the range of 37.5 to 150.0 µg/mL for ASP, 5.0 to 20.0 µg/mL for ATV and 25.0 to 100.0 µg/mL for ATL and LST. Acceptable precision and accuracy were obtained for concentrations over the standard curve ranges. The validated method was successfully applied to the analysis of Starpill tablets constituting all the four drugs; the percentage recoveries obtained were 99.60% for ASP, 99.30% for ATV, 99.41% for ATL and 99.62% for LST.
Cite this paper: nullS. Shetty, K. Surendranath, P. Radhakrishnanand, R. Borkar, P. Devrukhakar, J. Jogul and U. Tripathi, "Quantitative Application to a Polypill by the Development of Stability Indicating LC Method for the Simultaneous Estimation of Aspirin, Atorvastatin, Atenolol and Losartan Potassium," American Journal of Analytical Chemistry, Vol. 1 No. 2, 2010, pp. 59-69. doi: 10.4236/ajac.2010.12008.

[1]   N. J. Wald and M. R. Law, “A Strategy to Reduce Cardiovascular Disease by More Than 80 Percent,” British Medical Journal, Vol. 326, No. 7404, 2003, p. 1419.

[2]   G. Sanz and V. Fuster, “Fixed-Dose Combination Therapy and Secondary Cardiovascular Prevention: Rationale, Selection of Drugs and Target Population,” Nature Clinical Practice Cardiovascular Medicine, Vol. 6, No. 2, 2009, pp. 101-110.

[3]   S. Yusuf, P. Pais, R. Afzal, et al., “Effects of a Polypill (Polycap) on Risk Factors in Middle-Aged Individuals without Cardiovascular Disease (TIPS): A Phase II, Double-Blind, Randomised Trial,” Lancet, Vol. 373, No. 9672, 2009, pp. 341-351.

[4]   M. R. Law and N. J. Wald, “Risk factor thresholds: their existence under scrutiny,” British Medical Journal, Vol. 324, No. 7353, 2002, pp. 570-576.

[5]   V. Kumar, R. P. Shah and S. Singh, “LC and LC-MS Methods for the Investigation of Polypills for the Treatment of Cardiovascular Diseases: Part.1Separation of Active Compo,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 47, 2008, pp. 508-515.

[6]   V. Kumar, S. Malik and S. Singh, “Polypill for the treatment of cardiovascular diseases: Part 2. LC-MS/TOF characterization of interaction/degradation products of atenolol/lisinopril,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 48, No. 3, 2008, pp. 619-628.

[7]   M. C. Koester, “An Overview of the Physiology and Pharmacology of Aspirin and Nonsteroidal Anti-Inflammatory Drugs,” Journal of Athletic Training, Vol. 28, No. 3, 1993, pp. 252-254, 256-259.

[8]   S. P. Clissold, “Aspirin and Related Derivatives of Salicylic Acid,” Drugs, Vol. 32, Supplement 4, 1986, pp. 8- 26.

[9]   R. G. Bakker-Arkema, M. H. Davidson, R. J. Goldstein, “Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients with Hypertriglyceri- demia,” Journal of the American Medical Association, Vol. 275, No. 2, 1996, pp. 128-133.

[10]   A. N. Wadworth, D. Murdoch, R. N. Brogden, “Atenolol: A Reappraisal of its Pharmacological Properties and Therapeutic Use in Cardiovascular Disorders,” Drugs, Vol. 42, No. 3, 1991, pp. 468-510.

[11]   B. M. Psaty, T. D. Koepsell, J. P. LoGerfo, et al., “B-Blockers and Primary Prevention of Coronary Heart Disease in Patients with High Blood Pressure,” Journal of the American Medical Association, Vol. 261, No. 14, 1989, pp. 2087-2094.

[12]   K. L. Goa and A. J. Wag, “Losartan Potassium: A Review of its Pharmacology, Clinical Efficacy and Tolerability in the Management of Hypertension,” Drugs, Vol. 51, No. 5, 1996, pp. 820-845.

[13]   E. R. Montgomery, S. Taylor, J. Segretario, et al., “Development and Validation of a Reversed-Phase Liquid Chromatographic Method for Analysis of Aspirin and Warfarin in a Combination Tablet Formulation,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 15, No. 1, 1996, pp. 73-82.

[14]   D. G. Sankar, M. S. M. Raju, K. Sumanth and P. V. M. Latha, “Asian HPLC Method for Estimation of Atorvastatin in Pure and Pharmaceutical Dosage Form,” Journal of Chemistry, Vol. 17, 2005, pp. 2571-2574.

[15]   S. Erturk, A. E. Sevinc, L. Ersoy and S. Ficicioglu, “HPLC Method for the Determination of Atorvastatin and its Impurities in Bulk Drug and Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, 2003, pp. 1017-1023.

[16]   A. Puratchikody, R. Valarmathy, P. Shiju, “RP-HPLC Determination of Atorvastatin Calcium in Solid Dosage Forms,” Journal of Pharmaceutical Reviews, 2003, pp. 79-80.

[17]   B. Stanisz and L. Kania, “Validation of HPLC Method for Determination of Atorvastatin in Tablets and for Monitoring in Solid Phase,” Acta Poloniae Pharmaceutica, Vol. 63, No. 6, 2006, pp. 471-476.

[18]   G. Bahrami, B. Mohammadi, S. Mirzaeei and A. Kiani, “Determination of Atorvastatin in Human Serum by Reverse Phase High Performance Liquid Chromatography with UV Detection,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 826, 2005, pp. 41-45.

[19]   M. Jemal, Z. Ouyang, B. C. Chen and D. Teitz, “Quantitation of Atorvastatin and its Bio-Transformation Products in Human Serum by HPLC with Electro Spray Tandem Mass Spectrometry,” Rapid Communications in Mass Spectrometry, Vol. 13, 1999, pp. 1003-1015.

[20]   M. Hermann, H. Christensen and J. L. Reubsaet, “Determination of Atorvastatin and Metabolites in Human Plasma with Solid Phase Extraction Followed by LC- Tandem MS,” Analytical and Bioanalytical Chemistry, Vol. 382, No. 5, 2005, pp. 1242-1249.

[21]   S. R. Dhaneshwar, S. Yadav, A. Mhaske and S. Kadam, “HPTLC Method for Determination of Content Uni- formity of Atorvastatin Calcium Tablets,” Indian Journal of Pharmaceutical Sciences, Vol. 67, 2005, pp. 182-186.

[22]   C. V. N. Prasad, C. Parihar, K. Sunil and P. Parimoo, “Simultaneous Determination of Amiloride, Hydrochloro- thiazide and Atenolol in Combined Formulation by Derivative Spectroscopy,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 17, 1998, pp. 877-884.

[23]   S. M. Al-Ghannam, “A Simple Spectrophotometric Method for the Determination of B-Blockers in Dosage Forms,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 40, No. 1, 2006, pp. 151-156.

[24]   A. P. Agrekar and S. G. Powar, “Reverse Phase High Performance Liquid Chromatographic Determination of Ramipril and Amlodipine in Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 21, 2000, pp. 1137-1142.

[25]   M. B. Shankar, F. A. Metha, K. K. Bhatt, R. S. Metha and M. Geetha, “Simultaneous Spectrophotometric Determination of Losartan Potassium and Hydrochlorothiazide in Tablets,” Indian Journal of Pharmaceutical Sciences, Vol. 65, No. 2, 2003, pp. 167-170.

[26]   C. F. Pedroso, J. G. de Oliveira, F. R. Campos, et al., “A Validated RP-LC Method for Simultaneous Determination of Losartan Potassium and Amlodipine Besilate in Pharmaceutical Preparations,” Chromatography, Vol. 69, Supplement 2, pp. 201-206.

[27]   D. D. Rao, N. V. Satyanarayana, S. S. Sait, Y. R. Reddy and K. Mukkanti, “Simultaneous Determination of Losartan Potassium, Atenolol and Hydrochlorothiazide in Pharmaceutical Preparations by Stability-Indicating UPLC,” Chromatography, Vol. 70, No. 4, 2009, pp. 647-651.

[28]   “ICH Stability Testing of New Drug Substances and Products Q1A (R2),” International Conference on Harmonization, IFPMA, Geneva, 2003.

[29]   “ICH guidelines on Validation of Analytical procedures, Text and Methodology Q2 (R1),” FDA, Published in the Federal Register 60, 1995.

[30]   “United States Pharmacopoeia,” 32nd Edition, United States Pharmacopeial Convention, Rockville, 2009.

[31]   M. Bakshi and S. Singh, “Development of Validated Stability-Indicating Assay Methods-Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040.